FDA Approves Genentech’s Perjeta to Treat HER2-Positive Metastatic Breast Cancer

The FDA has approved Roche subsidiary Genentech’s Perjeta as part of a first-line treatment combination for patients with HER2-positive metastatic breast cancer. A combination of Perjeta (pertuzumab), Roche’s Herceptin (trastuzumab) and docetaxel chemotherapy is indicated for patients who have not received prior treatment for metastatic breast cancer with an anti-HER2 therapy or chemotherapy. HER2-positive cancer affects about 20 percent of women with breast cancer, the FDA said.
Drug Industry Daily